Edition:
India

People: Agios Pharmaceuticals Inc (AGIO.OQ)

AGIO.OQ on NASDAQ Stock Exchange Global Select Market

43.30USD
1:30am IST
Change (% chg)

$-0.81 (-1.84%)
Prev Close
$44.11
Open
$43.92
Day's High
$44.26
Day's Low
$43.09
Volume
222,329
Avg. Vol
263,461
52-wk High
$56.59
52-wk Low
$28.00

Fouse, Jacqualyn 

Dr. Jacqualyn A. Fouse Ph.D. serves as Chief Executive Officer, Director of the Company. Dr. Fouse served as executive chair of Dermavant Sciences, a biopharmaceutical company, from July 2017 until September 2018. From September 2010 until June 2017, Dr. Fouse served in various capacities at Celgene Corporation, a biopharmaceutical company, or Celgene, serving as strategic advisor to the management executive committee from April 2017 to June 2017, president and chief operating officer from March 2016 to March 2017, president, hematology and oncology from August 2014 to February 2016, executive vice president and chief financial officer from February 2012 to July 2014, and senior vice president and chief financial officer from September 2010 to February 2012. Prior to joining Celgene, Dr. Fouse served as chief financial officer of Bunge Limited, or Bunge, a global agribusiness and food company, from 2007 to 2010. Prior to joining Bunge, Dr. Fouse served as senior vice president, chief financial officer and corporate strategy at Alcon Laboratories, Inc., or Alcon, a global medical company, since 2006, and as its senior vice president and chief financial officer since 2002. Prior to her time with Alcon she held a variety of senior leadership roles with international companies. Dr. Fouse is also a director and member of the audit committee of Incyte and is a director and member of the audit committee of Dick’s Sporting Goods, Inc., a public sporting goods retailer, and was a director of Perrigo Company from November 2012 to April 2016 and a director of Celgene from February 2016 until June 2017. Dr. Fouse has informed us that she will not be standing for reelection to the board of directors of Dick’s Sporting Goods, Inc. at its upcoming annual meeting in June 2020. Dr. Fouse earned a B.A. and an M.A. in Economics and a Ph.D. in Finance from the University of Texas at Arlington. She also earned a Masters in Environmental Management from the Yale University School of Forestry and Environmental Studies.

Basic Compensation

Total Annual Compensation, USD 664,583
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 15,943,400
Fiscal Year Total, USD 16,608,000

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

David Schenkein

2,576,380

Jacqualyn Fouse

16,608,000

Andrew Hirsch

4,248,830

Bruce Car

--

Jonathan Biller

3,183,890

Christopher Bowden

3,227,210
As Of  31 Dec 2019